Oxford Properties sought to build a portfolio of Life Sciences R&D real estate in UK and were keen to understand the dynamics and opportunity areas in the market.
We acted for Oxford Properties in appraising investment opportunities that came to market in the key UK location of Cambridge. We also identified and sourced an off market opportunity to acquire a highly specified building let to AstraZeneca. We provided market advice on demand, supply and values that enabled the client to fully understand the potential of the asset.
The asset was acquired marking Oxford Properties first acquisition in the sector in the UK. We have subsequently been appointed as joint letting agents to secure a tenant following the anticipated departure of AZ to their new Cambridge facility.